IndraLab

Statements

Silibinin inhibits FOS. 1 / 1

| 1

reach

"More importantly, in an ectopic allograft model, oral administration of silibinin and DHS (200 mg/kg body weight) strongly inhibited the ASZ tumor growth by 44 and 71% (p < 0.05), respectively, and decreased the expression of proliferation biomarkers (PCNA and cyclin D1) as well as NF-kappaB p50 and c-Fos in the tumor tissues."

25492239

INDRA sources:

Colored badges next to statement headings correspond to evidence counts from knowledge sources, as shown below. Badges to the left of the | separator correspond to curated knowledge base sources, and badges to the right of it correspond to machine reading systems.

IndraLab

Statements

Silibinin inhibits FOS. 1 / 1

INDRA sources:

Databases

Reading